orchestrabiomed.com (OBIO) Enterprise Value to EBITDA Ratio
Orchestra BioMed (OBIO) is implementing sustainable packaging standards and energy efficiency across its cardiac device production. The business relies on partnerships with global behemoths to bring innovative hypertension treatments to market. Meanwhile, electronics supply chain stability and international certification remain critical factors. The current EV/EBITDA ratio stands at 0.00, as clearly illustrated by this price chart.
Comprehensive metric breakdowns and analytics for Orchestra BioMed Inc. (OBIO)
- current price and projected stock value:
- market capitalization details:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Orchestra BioMed|OBIO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Orchestra BioMed|OBIO - Company Total Debt|Debts to Book Capitalization Orchestra BioMed, Inc.|OBIO - Long-Term Debt|Company Short-Term Debts Orchestra BioMed|Quick Ratio orchestrabiomed.com
- financial results and valuation multiples details:
OBIO - Net Financial Result|Projected Future Earnings Orchestra BioMed|OBIO - Price to Earnings Ratio|Forward P/E Multiple Orchestra BioMed, Inc.|OBIO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Orchestra BioMed, Inc.|OBIO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Orchestra BioMed|OBIO - Earnings per share for the trailing year|Quarterly EPS earnings growth orchestrabiomed.com|OBIO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Orchestra BioMed
Analysis of all company metrics:Orchestra BioMed, Inc. OBIO
Moderate capacity utilization of Orchestra BioMed (OBIO) cardiology system assembly lines directly impacts operating profit generation. The estimated EV/EBITDA multiple relates the total enterprise value, accounting for all debts and taxes, to this income. This metric reveals hidden risks regarding prolonged price stability, reflecting the market consensus on the value of production capacities. Analysis of this chart allows a strategist to timely identify a low-volatility trap before a change in the industry leader.
Competitor analysis
EV/EBITDA Multiple BSX (Boston Scientific Inc)|Total Company Value to Operating Income Before Depreciation Ratio Edwards Lifesciences Inc. (EW)|RMD: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio PODD|ZBH: EV/EBITDA Multiple|Company Value to EBITDA The Cooper Companies, Inc. (COO)|ALGN (Align Technology Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation GMED (NuVasive)|Enterprise Value to EBITDA Ratio TMDX (TransMedics)|ATEC (atecspine.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artivion AORT|ENOV - Enterprise Value to EBITDA Ratio|Integra - EV/EBITDA Multiple|Company Value to EBITDA Establishment Labs Inc|BBNX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation IRMD|EMBC (Embecta) - EV/EBITDA Multiple|Tandem Diabetes Care Inc (TNDM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AXGN|Enterprise Value to EBITDA Ratio SI-BONE Medical SIBN|EV/EBITDA Multiple OFIX (Orthofix Medical Inc.)|EV/EBITDA Multiple bioventus.com BVS|KIDS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TMCI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRTA (Strata Critical Medical Corp) - Enterprise Value to EBITDA Ratio|Carlsmed Medical - Business Value to Operating Income Before Depreciation|RXST (RxSight, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA ClearPoint CLPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stereotaxis (STXS)|Neuronetics Inc. (STIM) - Enterprise Value to EBITDA Multiple|Sight Sciences, Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Anika Therapeutics Inc. ANIK|InspireMD, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Jin Medical International ZJYL|vivani.com (VANI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XTNT (Xtant Medical)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroOne Corp|Enterprise Value to EBITDA Ratio Modular Med (MODD)|EV/EBITDA Multiple MYO|COCH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vivos Therapeutics, Inc. VVOS|NVNO: Enterprise Value to Operating Income Before Depreciation|SINT: Enterprise Value to EBITDA Ratio|Tenon Medical Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ReWalk Robotics Ltd. (LFWD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Autonomix Medical (AMIX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INVO Fertility|BBLG: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple AXNX|Enterprise Value to EBITDA Ratio Biolase Inc. BIOL|EV/EBITDA Multiple DYNT (Dynatronics)|Business Value to Operating Income Before Depreciation FNA|INVO Bio - EV/EBITDA Multiple
